【作者单位】Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. '(1)' ; Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. [2] ; Dawu County People's Hospital, Xiaogan 432826, China. [3] ; State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China. [4] ; Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou 510623, China. [5] ; Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing 100871, China. [6] ; Department of Infectious Disease and Department of Pediatrics, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China. [7] ; Center for Innovative Marine Drug Screening & Evaluation (QNLM), School of Medicine and Pharmacy, Ocean University of China, Qingdao 266100, China. [8] ; Walter and Eliza Hall Institute of Medical Research and Department of Microbiology & Immunology, University of Melbourne, Parkville, Vic 3052, Australia. [9] ; School of Life Sciences, Sun Yat-sen University, Guangzhou 510006, China. [10] ; Cardiovascular Department, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China. [11] ; State Key Laboratory of Virology, College of Science, Innovation Center for Traditional Tibetan Medicine Modernization and Quality Control, Medical College, Tibet University, Lhasa 850000, China. [12] ; Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE), Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China. [13]
【关键词】COVID-19 D-dimer Dipyridamole SARS-CoV-2 Severe cases Treatment
【摘要】 Severe acute respiratory syndrome coronavirus 2 infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the...
